Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Investor Investigation Concerning Possible Wrongdoing In Acquisition Announced

If yo purchased shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) and currently hold any of those NASDAQ:RPTP shares, you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Raptor Pharmaceutical
Affected Securities: 
NASDAQ: RPTP

September 20, 2016 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP), was announced concerning whether the takeover of Raptor Pharmaceutical Corp. by Horizon Pharma plc for $9.00 per share is unfair to NASDAQ:RPTP stockholders.

The investigation by a law firm concerns whether certain officers and directors of Raptor Pharmaceutical Corp. breached their fiduciary duties owed toNASDAQ:RPTP investors in connection with the proposed acquisition.

On September 12, 2016, Horizon Pharma plc (NASDAQ:HZNP) and Raptor Pharmaceutical Corp. (NASDAQ:RPTP) announced the companies have entered into an agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) common stock for $9.00 per share in cash, for an implied fully diluted equity value of approximately $800 million.

However, given that at least one analyst has set the high target price for NASDAQ:RPTP shares at $11.00 per share and given that NASDAQ:RPTP shares reached as high as $16.00 per share in June 2015, the investigation concerns whether the offer is unfair to(NASDAQ:RPTP stockholders. More specifically, the investigation concerns whether the Raptor Pharmaceutical Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.